Roche collaborates with Ascidian for RNA exon editing therapeutics, acquiring Carmot Therapeutics for obesity

From Nasdaq: 2024-06-19 13:27:00

1. Roche Holdings collaborates with Ascidian Therapeutics for RNA exon editing therapeutics targeting neurological diseases, aiming to provide durable gene therapy with reduced risks. Initial payment of $42 million with potential $1.8 billion in milestones. Roche also acquired Carmot Therapeutics for $2.7 billion to expand into the obesity space.

2. Roche’s collaborations with MOMA Therapeutics and MediLink Therapeutics aim to identify novel drug targets for cancer treatment. Continued development of drugs like Vabysmo, Ocrevus, Hemlibra, and Polivy drive revenue growth amid biosimilar competition. Approval of new drugs crucial for Roche’s success, despite a 3.4% YTD share decline.

3. Better-ranked healthcare stocks include Ligand Pharmaceuticals, ALX Oncology Holdings, and Minerva Neurosciences. Ligand’s 2024 EPS estimate increased to $4.71 while ALX Oncology’s 2024 loss per share narrowed. Minerva Neurosciences also saw reduced loss per share estimates. Roche carries a Zacks Rank #4 (Sell) currently.

4. A Special Report highlights top dividend stocks for retirement, including well-established companies with solid fundamentals. Ligand beat earnings estimates in the past four quarters with an average surprise of 56.02%. ALX Oncology delivered an average negative earnings surprise of 8.83%. Minerva Neurosciences saw a 54.43% average negative surprise.



Read more at Nasdaq: Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics